Loading patent…
AssigneesCentre National De La Recherche Scientifique, Universite De Poitiers, University of Exeter
InventorsMIROSLAVA SPANOVA, THIERRY FERREIRA, ROMAIN CLEMENT, SHALINEE DHAYAL, NOËL MORGAN
Estimating the term…
The present invention relates to the field of medicine. It more particularly relates to the use of compounds for preventing and/or treating dyslipidemia in a subject, said dyslipidemia typically being linked to the excess presence in the biological membranes, including in the biological membranes of non-adipocyte cells, of fatty acids, in particular of saturated long-chain fatty acids, and/or of sterols. The invention also relates to compositions, in particular pharmaceutical compositions and food supplements or complements, comprising such compounds, and to the uses thereof for preventing and/or treating dyslipidemia. The compounds and compositions according to the invention can in particular be advantageously used for preventing and/or treating a pathological condition selected from metabolic syndrome and/or a symptom or abnormality characteristic of metabolic syndrome, preferably for preventing or treating type 2 diabetes mellitus or hepatic steatosis.
1-12. (canceled)
A method for treating or reducing the risk of dyslipidemia linked to the excess presence in biological membranes in a subject comprising a step of administering to the subject a compound comprising a polar head comprising at least one hydroxyl residue on which is grafted a single unsaturated fatty acid comprising between 16 and 24 carbon atoms and having 1 to 6 unsaturation(s) in the cis configuration, and wherein said compound i) does not allow the production of diunsaturated phospholipids in the membrane of the treated cells and ii) does not constitute a source of oleic acid for the treated cell.
A composition comprising a compound comprising a polar head comprising at least one hydroxyl residue on which is grafted a single unsaturated fatty acid comprising between 16 and 24 carbon atoms and having 1 to 6 unsaturation(s) in the cis configuration, wherein said compound i) does not allow the production of diunsaturated phospholipids in the membrane of the treated cells and ii) does not constitute a source of oleic acid for the treated cell, said composition being selected from a pharmaceutical composition and a functional food or food supplement.
Dependencies are inferred from the claim text.